Novartis(NVS) and Pathwork Dx Collaborate on Biomarkers
The Wall Street Journal reported on Friday that Novartis (NVS) will collaborate with Pathwork Diagnostics on the development of biomarkers across a range of cancer types that would capitalize on the trend to "match patients with the right medicines". Pathwork, a venture funded Company in...
“AACC Effect” Rally Rolls On: Abaxis(ABAX),GenProbe (GPRO),and Quidel (QDEL)
The intersection of good earnings and a strong AACC showing boosted Diagnostic stocks this week with the following big movers today on earnings reports: Abaxis (ABAX) $20.81 up $13.7%,GenProbe (GPRO) $45.85 up 8.14%,Neogen (NEOG) $29.85 up 3.4% and Quidel (QDEL) $12.34 up 3.5%.Bruker was also...
AACC Notes-Diagnostic Stocks and Rayno Model Portfolio
Here are some brief notes from our visit to the AACC in Anaheim and recent earnings reports. Rayno Diagnostic and Tools Portfolio Abaxis (ABAX)-under review- and Quidel (QDEL) report today.We added Quidel to our model portfolio on 6/16 at $12.40.The stock is trading at around $12 maybe...
AACC Meeting: Buzz Coming to Fuel the Rally In Diagnostic Stocks
The July 25-29 AACC (American Association of Clinical Chemistry) Meeting in Anaheim will have close to 20,000 clinical lab professionals and over 500 exhibitors . A stock rally in the sector was ignited last week by earnings announcements from four major mid-cap players and new product and...
Big Movers In Diagnostics Today: Immucor (BLUD) Up 6.5% and Cepheid (CPHD) up 12%
Good financials have perked up interest is mid-cap Diagnostics companies that released results today. Immucor (BLUD) a global leader in automated analysis of blood transfusion systems had revenue of $82.9M up 5% from prior year quarter with diluted earnings of $0.30 per share compared to $0.27...